Pfizer discontinues Metsera oral GLP-1 MET-224o and GIPR antagonist
The GIPR antagonist PF-07976016 was dropped after phase 2a data on a liraglutide background, leaving Pfizer with one oral GLP-1 candidate.
TR
By Tom Reyes · Markets Editor
Aug 4 03:00 ETSource: Fierce Biotech
The wire
- 01Pfizer cut MET-224o, an oral ultra-long-acting GLP-1 agonist acquired in the $10 billion Metsera deal, and phase 2 GIPR antagonist PF-07976016, plus an MC4R antagonist and a nephropathy asset.
- 02Only PF-08642534, the oral small molecule licensed from YaoPharma for $150 million upfront, remains as Pfizer's oral GLP-1 program, though the company says it stays committed to oral peptide approaches.
- 03Pfizer's lead obesity asset is phase 3 monthly injectable berobenatide; Chief Scientific Officer Chris Boshoff said an analysis suggests weight loss comparable to tirzepatide and potentially better than semaglutide.
From the source
Read at fiercebiotech.comPfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
Pfizer has axed two clinical-stage obesity programs, including a GLP-1 receptor agonist that came over in the $10 billion acquisition of Metsera.
